Published • loading... • Updated
Merck and Gilead Post HIV Milestone Amid Setback in Lung Cancer Program
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Merck and Gilead Post HIV Milestone Amid Setback in Lung Cancer Program
Merck and Gilead Sciences reported contrasting late-stage outcomes on Monday, pairing a promising advance in HIV treatment with the discontinuation of a high-profile lung cancer trial after underwhelming survival results. On the infectious disease front, the companies announced positive Phase 3 findings for their investigational once-weekly oral HIV regimen combining islatravir and lenacapavir. Results from […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
